BofA cuts Ionis Pharmaceuticals stock price target on trial miss
1 min read
The coverage · 3 reports
- Investing.comFirst reportBofA cuts Ionis Pharmaceuticals stock price target on trial miss ↗
- Investing.com
- Investing.comLatest
The story
BofA reduced its price target on Ionis Pharmaceuticals (IONS) after the company reported a clinical trial failure, a meaningful negative catalyst for a biotech that is already running at a -40.4% net margin and posting a -$2.38 diluted EPS on $943.7M in revenue (+33.8% YoY as of FY2025). The revenue growth rate is a bright spot, suggesting the partnered drug portfolio is generating real royalty and milestone income, but that narrative is complicated when a key pipeline asset stumbles.
The trial miss matters because Ionis is a platform company — its valuation is built on the promise of future pipeline readouts, not current earnings. When BofA cuts its target, it is signaling that the risk-adjusted value of that pipeline just declined. Other sell-side desks may follow, compressing the multiple further if consensus shifts.
The bull case rests on the revenue growth trajectory and the breadth of the RNA-targeted drug platform, which has multiple partnered programs with large-cap pharma. A single trial miss does not invalidate the entire pipeline, and the stock could have already discounted the bad news if the selloff was sharp. The bear case is that a -40.4% net margin business with negative EPS has no earnings floor to catch the stock, and further price-target cuts from remaining analysts could extend the drawdown.
Key items to watch: the magnitude of the price-target cut from BofA, whether other analysts follow with their own reductions, management's commentary on the failed trial's impact on development timelines, and whether insider buying emerges at lower levels as a contrarian signal. Until the sell-side consensus stabilizes, the path of least resistance remains uncertain.
The case — both sides
Revenue grew 33.8% YoY to $943.7M, demonstrating that the partnered royalty and milestone engine is functioning, and a single trial miss in a diversified pipeline does not necessarily impair the core platform thesis.
With -$2.38 diluted EPS and a -40.4% net margin, IONS has no earnings floor to absorb further price-target reductions if BofA's cut triggers a consensus reset across the sell-side covering the stock.
The house read
Leans bearIONS faces a price-target cut after a trial miss — the question is whether the selloff already prices the pipeline damage or whether further analyst downgrades extend the pressure on a name with no EPS floor.
Wrong ifStrong revenue growth (+33.8% YoY) could attract dip buyers who view the trial miss as asset-specific rather than platform-wide; any positive pipeline readout from a partnered program would quickly reverse the short thesis.
Published read · research, not advice